Live Analyst Rating Changes 1942 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sachin Jain
BofA
Sachin Jain
Bank of America Securities
Wall Street Analyst
★★☆☆☆
#2180
on 13Foresight · ranked by our own returns
22%
Success Rate
-22.9%
Average Return
2 of 9 calls profitable · -38.2% vs benchmark
📈 Across the calls we could measure, roughly 22% of Sachin Jain's ratings turned a profit when each position was held for 2 year — averaging -22.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

49 Buy 27 Hold 7 Sell
Sachin's Stock Coverage 18 ratings · 2026-06-23
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
FR:SAN
Sanofi
 Jun 22, 2026 HOLD Strong Buy
+35.8% avg upside
30 analysts
$92.00
25.36% Upside
 ·
CH:NOVN
Novartis AG
 Jun 11, 2026 BUY Buy
-10.8% avg upside
30 analysts
$140.00
14.97% Upside
 ·
NVS
Novartis
 Jun 11, 2026 BUY Hold
-8.2% avg upside
24 analysts
$173.25
16.25% Upside
 -4.2%
GB:GSK
GlaxoSmithKline
 Jun 09, 2026 HOLD Hold
-2.6% avg upside
25 analysts
$2350.00
22.37% Upside
 ·
GB:AZN
AstraZeneca
 Jun 09, 2026 BUY Strong Buy
+11.7% avg upside
26 analysts
$16500.00
22.68% Upside
 ·
GB:0QIU
Novo Nordisk
 Feb 05, 2026 HOLD Hold
+40.1% avg upside
28 analysts
$350.00
20.05% Upside
 ·
DE:BAYN
Bayer
 Dec 02, 2025 BUY Strong Buy
+33.2% avg upside
28 analysts
$35.00
7.66% Downside
 ·
GB:0MGB
Genmab A/S
 Nov 25, 2025 BUY Strong Buy
+31.7% avg upside
22 analysts
$2250.00
37.11% Upside
 ·
ES:GRF
Grifols
 Nov 25, 2025 BUY Hold
+63.2% avg upside
12 analysts
$10.60
17.92% Upside
 ·
GSK
GlaxoSmithKline
 Oct 29, 2025 SELL Hold
-14.2% avg upside
19 analysts
$22.48
55.79% Downside
 -13.4%
NVO
Novo Nordisk
 Oct 09, 2025 HOLD Hold
+158.8% avg upside
26 analysts
$57.55
25.38% Upside
 -18.9%
CH:ROP
Roche Holding AG
 Sep 13, 2024 BUY Strong Buy
+3.5% avg upside
23 analysts
$340.00
4.91% Upside
 ·
DE:MRK
Merck KGaA
 Jun 12, 2023 BUY Strong Buy
+2.1% avg upside
32 analysts
$205.00
54.48% Upside
 ·
GMAB
Genmab
 May 11, 2023 BUY Strong Buy
+37.2% avg upside
26 analysts
$48.50
89.38% Upside
 -53.9%
RCUS
Arcus Biosciences
 Feb 02, 2023 HOLD Strong Buy
+27.7% avg upside
20 analysts
$24.00
11.78% Downside
 -39.0%
MRNA
Moderna
 Jan 17, 2023 HOLD Hold
+15.8% avg upside
38 analysts
$195.00
228.68% Upside
 -82.1%
PFE
Pfizer
 Nov 01, 2022 BUY Buy
+34.7% avg upside
45 analysts
$60.00
139.26% Upside
 -35.5%
ACN
Accenture
 May 02, 2016 BUY Buy
+78.2% avg upside
42 analysts
 — +37.0%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sachin Jain — Frequently Asked Questions
How accurate are Sachin Jain's stock ratings?
Based on the calls 13Foresight could measure, about 22% of Sachin's ratings were profitable over a one-year hold, with an average return of -18.5% per rating, or -33.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sachin ranked on 13Foresight?
Sachin Jain is currently ranked #2180 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sachin cover?
Sachin most recently has ratings on FR:SAN, CH:NOVN, NVS, GB:GSK, GB:AZN, GB:0QIU, DE:BAYN, GB:0MGB, ES:GRF, GSK, NVO, CH:ROP and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.